FDA Alerts Providers to Recall of Compounded Drug Products
Coastal Meds LLC, which compounds drugs as an outsourcing facility, has voluntarily recalled all of its products marketed as sterile due to visible particles in some of the drug vials for injection, the Food and Drug Administration announced Friday. Health care providers should immediately quarantine and not administer any Coastal Meds sterile drug products intended for injection, FDA said. The agency encourages health care professionals and patients to report any adverse reactions or quality problems to the MedWatch program.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…